Monographie - Dactinomycin

Ostatnia aktualizacja :
08/05/2024

Dactinomycin

Struktura chemiczna

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cosmegen	Argentyna, Australia, Austria, Finlandia, Francja , Grecja, Iran, Kanada, Malezja, Meksyk, Norwegia, Nowa Zelandia, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja, Włochy
Cosmegen Lyovac	Irlandia, Rumunia, Wielka Brytania
Dacilon	Chile, Indie, Peru
Dacmozen	Indie
Dactino	Indie
Dactinomicina	Chile, Ekwador, KolumbiaKolumbia, Peru
Dactinomycin	Nowa Zelandia
Lyovac Cosmegen	Belgia, Holandia, Luksemburg, Niemcy

Bibliografia : Dactinomycin

	Typ	Publikacja
3	Czasopismo	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84	Czasopismo	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Czasopismo	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Czasopismo	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Czasopismo	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Czasopismo	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Czasopismo	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Czasopismo	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Czasopismo	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Czasopismo	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Czasopismo	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
729	Czasopismo	Rusmin S, Welton S, DeLuca P, DeLuca PP. Effect of inline filtration on the potency of drugs administered intravenously. Am J Hosp Pharm 1977 ; 34: 1071-1074.
857	Czasopismo	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	Czasopismo	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1178	Czasopismo	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322	Czasopismo	Ennis CE, Merritt RJ, Neff DN. In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. JPEN 1983 ; 7: 156-158.
1410	Czasopismo	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Czasopismo	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
4153	Laboratorium	Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics Orphan Europe (UF) Limited 2014

Mentions Légales